Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer

Dino Amadori, Rosella Silvestrini, Mario De Lena, Francesco Boccardo, Andrea Rocca, Emanuela Scarpi, Francesco Schittulli, Mario Brandi, Roberta Maltoni, Patrizia Serra, Riccardo Ponzone, Nicoletta Biglia, Lorenzo Gianni, Amelia Tienghi, Maria Rosaria Valerio, Paola Bonginelli, Laura Amaducci, Marina Faedi, Editta Baldini, Angelo Paradiso

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences